Register
Login:
Share:
Email Facebook Twitter




BTG Share Chat (BTG)

BTG Share Chat - RSS Feed

Share Price: 565.50Bid: 565.00Ask: 565.50Change: 3.50 (+0.62%)Riser - Btg
Spread: 0.50Spread as %: 0.09%Open: 560.00High: 571.00Low: 560.00Yesterday’s Close: 562.00


Share Discussion for BTG


Thread View

Please login or register to post a message on Share Chat.

Posts per page:

jumbo89
Posts: 44
Observation
Opinion:No Opinion
Price:615.00
one month on
14 Jan '16
One month on and I am still looking for broker upgrades. Is there anybody out there?
 
MickTKipper
Posts: 2,106
Off Topic
Opinion:Strong Buy
Price:667.00
BTG, already talked up for the week
16 Dec '15
Watch for broker upgrades.
MickTKipper
Posts: 2,106
Off Topic
Opinion:Strong Buy
Price:641.50
RE: BTG, Broker Updates..........
15 Dec '15
<b>BTG plc 17.8% Potential Upside Indicated by Deutsche Bank
Posted by: Amilia Stone 15th December 2015</b>

BTG plc with EPIC/TICKER LON:BTG has had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘BUY’ this morning by analysts at Deutsche Bank. BTG plc are listed in the Health Care sector within UK Main Market. Deutsche Bank have set their target price at 755 GBX on its stock. This would imply the analyst believes there is now a potential upside of 17.8% from the opening price of 641 GBX. Over the last 30 and 90 trading days the company share price has increased 95.5 points and decreased 3 points respectively.

BTG plc LON:BTG has a 50 day moving average of 584.88 GBX and the 200 Day Moving Average price is recorded at 669.43 GBX. The 1 year high share price is 835.87 GBX while the year low share price is currently 504 GBX. There are currently 382,957,017 shares in issue with the average daily volume traded being 585,096. Market capitalisation for LON:BTG is £2,454,754,479 GBP.

BTG plc is a specialist healthcare company. The Company operates in three business segments: Interventional Medicine (IM) (oncology, vascular and pulmonology products), Specialty Pharmaceuticals (antidote products) and Licensing (royalties from licensed assets). The Company’s Interventional Medicine segment offers a portfolio of interventional medicine products that are designed to advance the treatment of liver tumors, advanced emphysema, severe blood clots and varicose veins.
MickTKipper
Posts: 2,106
Off Topic
Opinion:Strong Buy
Price:641.00
RE: BTG, ANALYST UPGRADE...
15 Dec '15
<b>BTG plc (BTG) Receives Overweight Rating from JPMorgan Chase & Co.
December 15th, 2015 • 0 comments • Filed Under • by ABMN Staff</b>

BTG plc logoBTG plc (LON:BTG)‘s stock had its “overweight” rating reiterated by analysts at JPMorgan Chase & Co. in a research report issued on Tuesday, MarketBeat.com reports.

Several other research firms have also issued reports on BTG. Jefferies Group lowered their price target on shares of BTG plc from GBX 950 ($14.32) to GBX 850 ($12.81) and set a “buy” rating on the stock in a research report on Thursday, September 17th. Stifel Nicolaus reissued a “hold” rating on shares of BTG plc in a research report on Monday. Deutsche Bank boosted their price target on shares of BTG plc from GBX 750 ($11.30) to GBX 755 ($11.38) and gave the company a “buy” rating in a research report on Monday. Finally, Panmure Gordon lowered their price target on shares of BTG plc from GBX 1,035 ($15.60) to GBX 800 ($12.06) and set a “buy” rating on the stock in a research report on Tuesday, November 10th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of GBX 779.20 ($11.74).

BTG plc (LON:BTG) opened at 623.50 on Tuesday. The company’s market cap is GBX 2.38 billion. The company has a 50-day moving average of GBX 583.22 and a 200 day moving average of GBX 626.33. BTG plc has a 52 week low of GBX 504.00 and a 52 week high of GBX 835.87.

BTG plc is a specialist healthcare company. The Company operates in three business segments: Interventional Medicine (LON:BTG) (oncology, vascular and pulmonology products), Specialty Pharmaceuticals (antidote products) and Licensing (royalties from licensed assets). The Company’s Interventional Medicine segment offers a portfolio of interventional medicine products that are designed to advance the treatment of liver tumors, advanced emphysema, severe blood clots and varicose veins. The Company’s Specialty Pharmaceuticals segment offers a portfolio of antidote products that alleviate toxicity and treat rare conditions. The Company’s Licensing segment receives royalties relating to the sales of products that are subject to intellectual property and license agreements between the Company and various partners. The Company’s subsidiaries include BTG International (Holdings) Ltd, Provensis Ltd, BTG International Ltd and BTG Employee Share Schemes Ltd, among others.
MickTKipper
Posts: 2,106
Off Topic
Opinion:Strong Buy
Price:641.00
RE: BTG, ANALYST UPGRADE...
15 Dec '15
<b>BTG plc (BTG) Receives Overweight Rating from JPMorgan Chase & Co.
December 15th, 2015 • 0 comments • Filed Under • by ABMN Staff</b>

BTG plc logoBTG plc (LON:BTG)‘s stock had its “overweight” rating reiterated by analysts at JPMorgan Chase & Co. in a research report issued on Tuesday, MarketBeat.com reports.

Several other research firms have also issued reports on BTG. Jefferies Group lowered their price target on shares of BTG plc from GBX 950 ($14.32) to GBX 850 ($12.81) and set a “buy” rating on the stock in a research report on Thursday, September 17th. Stifel Nicolaus reissued a “hold” rating on shares of BTG plc in a research report on Monday. Deutsche Bank boosted their price target on shares of BTG plc from GBX 750 ($11.30) to GBX 755 ($11.38) and gave the company a “buy” rating in a research report on Monday. Finally, Panmure Gordon lowered their price target on shares of BTG plc from GBX 1,035 ($15.60) to GBX 800 ($12.06) and set a “buy” rating on the stock in a research report on Tuesday, November 10th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of GBX 779.20 ($11.74).

BTG plc (LON:BTG) opened at 623.50 on Tuesday. The company’s market cap is GBX 2.38 billion. The company has a 50-day moving average of GBX 583.22 and a 200 day moving average of GBX 626.33. BTG plc has a 52 week low of GBX 504.00 and a 52 week high of GBX 835.87.

BTG plc is a specialist healthcare company. The Company operates in three business segments: Interventional Medicine (LON:BTG) (oncology, vascular and pulmonology products), Specialty Pharmaceuticals (antidote products) and Licensing (royalties from licensed assets). The Company’s Interventional Medicine segment offers a portfolio of interventional medicine products that are designed to advance the treatment of liver tumors, advanced emphysema, severe blood clots and varicose veins. The Company’s Specialty Pharmaceuticals segment offers a portfolio of antidote products that alleviate toxicity and treat rare conditions. The Company’s Licensing segment receives royalties relating to the sales of products that are subject to intellectual property and license agreements between the Company and various partners. The Company’s subsidiaries include BTG International (Holdings) Ltd, Provensis Ltd, BTG International Ltd and BTG Employee Share Schemes Ltd, among others.
MickTKipper
Posts: 2,106
Off Topic
Opinion:Strong Buy
Price:642.00
BTG, Broker Updates..........
15 Dec '15
BTG broker views

Date Broker Recommendation Price Old target price New target price Notes
15 Dec Deutsche Bank Buy 640.50 755.00 755.00 Reiterates
15 Dec JP Morgan Cazenove Overweight 640.50 - - Reiterates
14 Dec Jefferies International Buy 640.50 850.00 850.00 Reiterates
14 Dec Stifel Hold 640.50 - - Reiterates
14 Dec Deutsche Bank Buy 640.50 750.00 755.00 Reiterates
cj101
Posts: 52
Observation
Opinion:No Opinion
Price:641.50
Deutsche bank
15 Dec '15
MickTKipper
Posts: 2,106
Off Topic
Opinion:Strong Buy
Price:639.00
BTG, ANALYST UPGRADE...
15 Dec '15
BTG plc (BTG) Receives Overweight Rating from JPMorgan Chase ...
43 minutes ago

... .......http://www.dakotafinancialnews.com/btg-plc-btg-receives-overweight-rating-from-jpmorgan-chase-co/727199/
MickTKipper
Posts: 2,106
Off Topic
Opinion:Strong Buy
Price:623.50
BTG, CITYWIRE COMMENT.....
15 Dec '15
<b>BTG gets early approval on overdose antidote</b>

Drug developer BTG (BTG) has received approval for its toxicity antidote drug Vistogard three months early.

Deutsche Bank analyst Richard Parkes retained his ‘buy’ recommendation and upped his target price to 755p from 750p. The shares fell 1.5p to 623.5p yesterday.

‘Approval by the [US] Food and Drug Administration… provides a welcome positive surprise, coming three months ahead of the expected… action date,’ he said.

‘The decision makes it the only approved emergency treatment for accidental overdose or severe toxicity with the cancer treatments fluorouracil or capecitabine.

‘The drug will be marketed via BTG’s speciality pharmaceuticals division, which sells similar antidote therapies…to US hospitals and emergency rooms. Given synergies with BTG’s existing portfolio and sales force, we expect the launch to require minimal investment.’

http://citywire.co.uk/money/the-expert-view-rolls-royce-hammerson-and-cobham/a867279?ref=citywire-money-latest-news-list#i=3
MickTKipper
Posts: 2,106
Off Topic
Opinion:Strong Buy
Price:623.50
BTG Broker Updates........
15 Dec '15
BTG Broker Updates.....

BTG PLC BTG Deutsche Bank Buy 623.50 623.50 755.00 755.00 Reiterates

BTG PLC BTG JP Morgan Cazenove Overweight 623.50 623.50 - - Reiterate




Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk






Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.